Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) have been assigned an average recommendation of “Hold” from the eighteen brokerages that are covering the stock, Marketbeat reports. Fifteen investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $43.78.
A number of analysts have recently commented on the company. Barclays cut their price objective on Sage Therapeutics from $311.00 to $294.00 in a research report on Monday, August 7th. Mizuho boosted their price target on Sage Therapeutics from $19.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, September 7th. Canaccord Genuity Group reiterated a “hold” rating and set a $21.00 price target (down from $64.00) on shares of Sage Therapeutics in a research report on Tuesday, August 8th. StockNews.com upgraded Sage Therapeutics to a “sell” rating in a research report on Monday, October 30th. Finally, HC Wainwright dropped their price target on Sage Therapeutics from $50.00 to $27.00 in a research report on Tuesday, August 8th.
Hedge Funds Weigh In On Sage Therapeutics
Sage Therapeutics Price Performance
Sage Therapeutics stock opened at $19.72 on Tuesday. The stock has a market capitalization of $1.18 billion, a PE ratio of -1.80 and a beta of 1.12. Sage Therapeutics has a 12 month low of $16.51 and a 12 month high of $59.99. The business has a 50 day simple moving average of $19.61 and a 200-day simple moving average of $33.26.
Sage Therapeutics Company Profile
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases.
- Five stocks we like better than Sage Therapeutics
- Investing in Agriculture 101: How to Invest in Agriculture
- Safeguard your portfolio with these three bargain stocks
- How to Invest in Hotel Stocks
- Membership clubs gain leverage for the consumer rebound
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.